Pulmonary Vascular Disease Clinical Trials

As a patient at Cedars-Sinai, you will have access to the latest clinical trials and research for pulmonary vascular disease. Backed by a respected team of specialists and researchers, our clinical trials aim to further the advancement of diagnosing and treating your condition.

Questions? See the Clinical Trials FAQs.

Condition:

Idiopathic, heritable, connective tissue disease-associated and HIV-associated pulmonary arterial hypertension

Key Inclusion Criteria

  • Confirmed clinical diagnosis of IPAH, HPAH, PAH-CTD, PAH-HIV
  • NYHA Functional Class: II or III
  • 18-75 years old

Summary:

This study focuses on patients with pulmonary arterial hypertension (PAH) from the following subgroups: idiopathic PAH (IPAH), heritable PAH (HPAH), PAH associated with connective tissue disease (PAH-CTD) and PAH associated with HIV (PAH-HIV). The study is designed to evaluate the investigational use of a biologic product called CAP-1002. CAP-1002 consists largely of heart stem cells ("CDCs") grown from donated tissue from human heart muscle. The purpose of the study is to determine the maximum feasible dose and safety of CAP-1002 administered by central intravenous infusion (IV line) in PAH patients belonging to one of the subgroups listed above who have been started on PAH-specific medications. CAP-1002 will be used in addition to the participant’s regular treatment regimen.

Condition:

Pulmonary hypertension

Key Inclusion Criteria

  • At least 18 years old
  • Females must not be pregnant or lactating; males and females must use contraception
  • Confirmed diagnosis of World Health Organization (WHO) Group 3 pulmonary hypertension

Summary:

The purpose of this study is to evaluate the safety of a drug called treprostinil (Tyvaso) and the effectiveness of inhaled treprostinil in patients with pulmonary hypertension (PH) associated with interstitial lung disease (ILD) or combined pulmonary fibrosis and emphysema (CPFE). Researchers will examine the participant's ability to exercise after taking treprostinil.